The price of Nektar Therapeutics (NASDAQ:NKTR) shares last traded on Wall Street fell -7.46% to $0.67.
Based on available information, 10 analysts follow Nektar Therapeutics (NASDAQ:NKTR). The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.75, we find $1.75. Given the previous closing price of $0.73, this indicates a potential upside of 139.73 percent. NKTR stock price is now -18.49% away from the 50-day moving average and -73.97% away from the 200-day moving average. The market capitalization of the company currently stands at $118.35M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 7 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $2.38 as their price target over the next twelve months.
.
In other news, ROBIN HOWARD W, President & CEO sold 20,361 shares of the company’s stock on May 16. The stock was sold for $14,660 at an average price of $0.72. Upon completion of the transaction, the President & CEO now directly owns 939,797 shares in the company, valued at $0.63 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, Chief R&D Officer Zalevsky Jonathan sold 9,791 shares of the business’s stock. A total of $7,050 was realized by selling the stock at an average price of $0.72. This leaves the insider owning 293,388 shares of the company worth $0.2 million. Insiders disposed of 257,913 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NKTR stock. A new stake in Nektar Therapeutics shares was purchased by DEEP TRACK CAPITAL, LP during the first quarter worth $1,175,000. ORBIMED ADVISORS LLC invested $697,000 in shares of NKTR during the first quarter. In the first quarter, DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT acquired a new stake in Nektar Therapeutics valued at approximately $195,000. CAPTION MANAGEMENT, LLC acquired a new stake in NKTR for approximately $118,000. WALLEYE TRADING LLC purchased a new stake in NKTR valued at around $56,000 in the second quarter. In total, there are 303 active investors with 94.80% ownership of the company’s stock.
A candlestick chart of Nektar Therapeutics (NASDAQ: NKTR) showed a price of $0.7300 on Tuesday morning. During the past 12 months, Nektar Therapeutics has had a low of $0.60 and a high of $5.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.20, and a quick ratio of 7.90. The fifty day moving average price for NKTR is $0.8166 and a two-hundred day moving average price translates $2.5684 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.73, missing analysts’ expectations of -$0.25 by -0.48. This compares to -$0.49 EPS in the same period last year. The company reported revenue of $21.59 million for the quarter, compared to $24.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.0 percent. For the current quarter, analysts expect NKTR to generate $21.07M in revenue.
Nektar Therapeutics(NKTR) Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
